Studying an extra COVID-19 vaccine dose in people with autoimmune diseases

An NIH study, co-led by a Michigan Medicine researcher, will follow participants over 13 months.

2:45 PM

Author | Noah Fromson

Nurse holding syringe vials with vaccine in clinic.

In recent months, mounting evidence has suggested the standard two-dose regimen for mRNA COVID-19 vaccines does not offer as much protection for immunocompromised people as it does for the general population.

Despite making up less than 3% of the U.S. adult population, immunocompromised people account for nearly 45% of breakthrough COVID-19 infections requiring hospitalization.

Given the available data, the Centers for Disease Control and Prevention has recommended that people who are moderately to severely immunocompromised receive a third dose of the mRNA vaccine. The FDA authorized the additional dose August 12.

Like Podcasts? Add the Michigan Medicine News Break on iTunes or anywhere you listen to podcasts.

The recommendation is based on a few studies that suggest immunocompromised people will produce higher levels of antibodies after a third dose. However, there are no control trials that focus specifically on the antibody responses to additional shots by those with autoimmune disease.

Now, a team of researchers co-led by a Michigan Medicine rheumatologist is launching a national trial to explore just that.

The focus of the study will be on Americans with autoimmune disease who did not present a strong immune response to two doses of the Pfizer-BioNTech vaccine, two doses of the Moderna vaccine or one dose of the Johnson & Johnson/Janssen vaccine. The Phase II trial is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. It will be co-led by Dinesh Khanna, M.B.B.S., M.Sc., the Frederick G.L. Huetwell professor of rheumatology and the director of the scleroderma program at Michigan Medicine.

"Although the FDA has recently approved booster vaccines for immunocompromised patients under emergency use authorization, there are several advantages for patients to participate in this 12-month adaptive trial design," Khanna said. "It allows us to carefully evaluate if the patients respond to the booster vaccine, continue to assess for durability of the vaccine over time and assess risk of flare of the underlying autoimmune disease."

The clinical trial to assess efficacy of a third COVID vaccine dose will include approximately 600 adult participants with one of five autoimmune diseases:

  • multiple sclerosis

  • pemphigus

  • rheumatoid arthritis

  • systemic lupus erythematosus

  • systemic sclerosis

Trial participants, who will be followed for 13 months, must be on immunosuppressive therapies and have demonstrated poor antibody response to an authorized COVID-19 vaccine regimen. Those medications include mycophenolate mofetil (MMF) or mycophenolic acid (MPA), methotrexate (MTX), or B cell-depleting drugs.

The research team will also examine whether pausing immunosuppressive medication improves immune response to the booster shot.

MORE FROM THE LAB: Subscribe to our weekly newsletter

"To hold or withhold the immunosuppressive therapies is an important issue for patients with autoimmune disease," Khanna said. "On one hand, it may improve the response to the booster, and on the other hand, it may lead to disease flare. This trial will carefully evaluate this in a controlled fashion."

Preliminary results are expected in November of 2021.

For more information about the COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders trial, go to ClinicalTrials.gov and use NCT05000216 as an identifier.


More Articles About: Lab Report Covid-19 Immunizations Vaccines and Immunizations Immune Deficiency infectious disease
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories Illustration of scientists and doctors playing basketball in white coats and scrubs
News Release
Four U-M teams selected for virtual tournament of science
U-M researchers' work made the bracket in the 2024 STAT Madness tournament of science, and need public support to advance
Health care provider loads syringe with measles vaccine
Health Lab
Measles: 10 things to know about immunization and prevention
Measles: 10 things to know about immunization and prevention
Minding Memory with a microphone and a shadow of a microphone on a blue background
Minding Memory
The Intersection of Artificial Intelligence & Alzheimer’s Disease and Related Dementias
In this episode, Matt and Donovan talk with Dr. Jason H. Moore, Director of the Center for Artificial Intelligence Research and Education (CAIRE) and Chair of the Department of Computational Biomedicine at Cedars-Sinai Medical Center. Jason discusses the coming impact of artificial intelligence on a spectrum of Alzheimer’s disease and related dementia (ADRD) issues. We discuss how tools such as AI-powered chatbots may improve quality of life for people living with dementia (and their caregivers) and how AI may contribute in the future to diagnosis and treatment.
colorful illustration with human figure and highlighted lungs
Health Lab
Multimodal AI model may guide personalized treatments for tuberculosis
AI approach helps researchers interpret large biomedical data sets to accurately predict tuberculosis treatment prognosis
Provider takes a pulse oximetry reading from a patient's finger
Health Lab
Inaccurate pulse oximeter readings could limit transplants, heart pumps for Black patients with heart failure
Racially biased readings of oxygen levels in the blood using pulse oximeters may further limit opportunities for Black patients with heart failure to receive potentially lifesaving treatments, such as heart pumps and transplants
Medical gloved hand holding test tube sample for HIV testing.
Health Lab
Inequities in HIV testing, diagnosis and care for people with intellectual and developmental disabilities
People with disabilities are often at higher risk for exposure to HIV due to barriers in engaging healthcare and other systemic factors and are thus considered a priority for prevention and testing efforts. However, these efforts don’t always extend to people with intellectual disabilities due to the perception that people with intellectual disabilities are mostly asexual.